SPA
IOVA icon

Sherbrooke Park Advisers’s Iovance Biotherapeutics IOVA Stock Holding History

Sherbrooke Park Advisers’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-19,090
Closed -$141K – 761
2024
Q4 		$141K Buy
+19,090
New +$177K 0.05% 632

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Sherbrooke Park Advisers's IOVA Position: Q1 2025 in Review

Sherbrooke Park Advisers sold out of Iovance Biotherapeutics (IOVA) in Q1 2025, closing a stake of 19,090 shares — an estimated $141K sold.

Sherbrooke Park Advisers first reported a position in IOVA in Q4 2024 and held it in 1 quarter. The position peaked at $141K in Q4 2024. 301 funds tracked by Wall St. Rank hold IOVA as of Q1 2025.

  • Sherbrooke Park Advisers reported no remaining Iovance Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 19,090 Iovance Biotherapeutics shares in Q1 2025, an estimated $141K.
  • Sherbrooke Park Advisers first reported a position in Iovance Biotherapeutics in Q4 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Iovance Biotherapeutics position peaked at $141K in Q4 2024.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2025, filed 15 May 2025.